{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2
  ],
  "modelUsed": "gemini-2.5-pro",
  "metadata": {
    "studyName": "MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF FULVESTRANT (FASLODEX) ",
    "titles": [
      {
        "id": "title_1",
        "text": "MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF FULVESTRANT (FASLODEX) WITH OR WITHOUT PD-0332991 (PALBOCICLIB) GOSERELIN IN WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY",
        "type": {
          "code": "Official Study Title",
          "codeSystem": "USDM",
          "decode": "Official Study Title"
        },
        "instanceType": "StudyTitle"
      },
      {
        "id": "title_2",
        "text": "PALOMA-3",
        "type": {
          "code": "Study Acronym",
          "codeSystem": "USDM",
          "decode": "Study Acronym"
        },
        "instanceType": "StudyTitle"
      }
    ],
    "identifiers": [
      {
        "id": "sid_1",
        "text": "69,324",
        "scopeId": "org_3",
        "instanceType": "StudyIdentifier",
        "identifierType": {
          "code": "IND",
          "codeSystem": "USDM",
          "decode": "FDA IND Number"
        }
      },
      {
        "id": "sid_2",
        "text": "2013-002580-26",
        "scopeId": "org_2",
        "instanceType": "StudyIdentifier",
        "identifierType": {
          "code": "EudraCT",
          "codeSystem": "USDM",
          "decode": "EudraCT Number"
        }
      },
      {
        "id": "sid_3",
        "text": "A5481023",
        "scopeId": "org_1",
        "instanceType": "StudyIdentifier",
        "identifierType": {
          "code": "SponsorProtocolNumber",
          "codeSystem": "USDM",
          "decode": "Sponsor Protocol Number"
        }
      }
    ],
    "organizations": [
      {
        "id": "org_1",
        "name": "Pfizer",
        "type": {
          "id": "2472fd07-0df4-4c35-a21d-896acaca93b0",
          "code": "C54086",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Pharmaceutical Company",
          "instanceType": "Code"
        },
        "identifier": "Pfizer",
        "identifierScheme": "DUNS",
        "instanceType": "Organization"
      },
      {
        "id": "org_2",
        "name": "EudraCT",
        "type": {
          "id": "cc9a18f6-f68c-40fb-903d-fc4e1a380905",
          "code": "C19326",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Healthcare Facility",
          "instanceType": "Code"
        },
        "identifier": "EudraCT",
        "identifierScheme": "DUNS",
        "instanceType": "Organization"
      },
      {
        "id": "org_3",
        "name": "FDA",
        "type": {
          "id": "0f567ed4-ce28-438a-a6e5-c755f804ddd5",
          "code": "C25461",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Regulatory Agency",
          "instanceType": "Code"
        },
        "identifier": "FDA",
        "identifierScheme": "DUNS",
        "instanceType": "Organization"
      }
    ],
    "roles": [
      {
        "id": "role_1",
        "name": "Sponsor",
        "code": {
          "code": "Sponsor",
          "codeSystem": "USDM",
          "decode": "Sponsor"
        },
        "organizationIds": [
          "org_1"
        ],
        "instanceType": "StudyRole"
      },
      {
        "id": "role_2",
        "name": "Registry",
        "code": {
          "code": "Sponsor",
          "codeSystem": "USDM",
          "decode": "Sponsor"
        },
        "organizationIds": [
          "org_2"
        ],
        "instanceType": "StudyRole"
      },
      {
        "id": "role_3",
        "name": "Regulatory Authority",
        "code": {
          "code": "Regulatory Agency",
          "codeSystem": "USDM",
          "decode": "Regulatory Agency"
        },
        "organizationIds": [
          "org_3"
        ],
        "instanceType": "StudyRole"
      }
    ],
    "indications": [
      {
        "id": "ind_1",
        "name": "Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer",
        "isRareDisease": false,
        "instanceType": "Indication",
        "description": "Women with hormone receptor-positive, HER2-negative metastatic breast cancer whose disease progressed after prior endocrine therapy"
      }
    ],
    "studyPhase": {
      "code": "Phase3",
      "codeSystem": "USDM",
      "decode": "Phase3"
    },
    "studyType": "Interventional"
  },
  "rawResponse": {
    "titles": [
      {
        "id": "title_1",
        "text": "MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF FULVESTRANT (FASLODEX) WITH OR WITHOUT PD-0332991 (PALBOCICLIB) GOSERELIN IN WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY",
        "type": {
          "code": "OfficialStudyTitle",
          "codeSystem": "http://www.cdisc.org/USDM/titleType",
          "decode": "Official Study Title"
        },
        "instanceType": "StudyTitle"
      },
      {
        "id": "title_2",
        "text": "PALOMA-3",
        "type": {
          "code": "StudyAcronym",
          "codeSystem": "http://www.cdisc.org/USDM/titleType",
          "decode": "Study Acronym"
        },
        "instanceType": "StudyTitle"
      }
    ],
    "identifiers": [
      {
        "id": "sid_1",
        "text": "69,324",
        "identifierType": "IND",
        "issuingOrganization": "FDA",
        "instanceType": "StudyIdentifier"
      },
      {
        "id": "sid_2",
        "text": "2013-002580-26",
        "identifierType": "EudraCT",
        "issuingOrganization": "EudraCT",
        "instanceType": "StudyIdentifier"
      },
      {
        "id": "sid_3",
        "text": "A5481023",
        "identifierType": "SponsorProtocolNumber",
        "issuingOrganization": "Pfizer",
        "instanceType": "StudyIdentifier"
      }
    ],
    "organizations": [
      {
        "id": "org_1",
        "name": "Pfizer",
        "type": {
          "code": "Sponsor",
          "codeSystem": "http://www.cdisc.org/USDM/organizationType",
          "decode": "Sponsor"
        },
        "role": "Sponsor",
        "instanceType": "Organization"
      },
      {
        "id": "org_2",
        "name": "EudraCT",
        "type": {
          "code": "Registry",
          "codeSystem": "http://www.cdisc.org/USDM/organizationType",
          "decode": "Clinical Study Registry"
        },
        "role": "Registry",
        "instanceType": "Organization"
      },
      {
        "id": "org_3",
        "name": "FDA",
        "type": {
          "code": "RegulatoryAuthority",
          "codeSystem": "http://www.cdisc.org/USDM/organizationType",
          "decode": "Regulatory Authority"
        },
        "role": "Regulatory Authority",
        "instanceType": "Organization"
      }
    ],
    "studyPhase": {
      "code": "Phase3",
      "codeSystem": "http://www.cdisc.org/USDM/studyPhase",
      "decode": "Phase 3"
    },
    "studyType": "Interventional",
    "indication": {
      "id": "ind_1",
      "name": "Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer",
      "description": "Women with hormone receptor-positive, HER2-negative metastatic breast cancer whose disease progressed after prior endocrine therapy",
      "instanceType": "Indication"
    }
  }
}